Nurix Therapeutics宣布，其与罗氏（Roche）达成的全球合作协议已获得美国《哈特-fullName-斯科特-罗迪诺反垄断改进法》（HSR）的批准。该合作旨在共同开发并商业化潜在同类最佳的布鲁顿酪氨酸激酶（BTK）降解剂Bexobrutideg，其应用范围将广泛覆盖恶性血液病、免疫学及神经学等多个治疗领域。
Nurix Therapeutics宣布，其与罗氏（Roche）达成的全球合作协议已获得美国《哈特-fullName-斯科特-罗迪诺反垄断改进法》（HSR）的批准。该合作旨在共同开发并商业化潜在同类最佳的布鲁顿酪氨酸激酶（BTK）降解剂Bexobrutideg，其应用范围将广泛覆盖恶性血液病、免疫学及神经学等多个治疗领域。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.